Drug updated on 11/17/2023

Dosage FormInjection (subcutaneous; 3 mg/1.5 mL (2 mg/mL) in a single-dose vial, 40 mg/mL in a single-dose vial)
Drug ClassBispecific GPRC5D-directed CD3 T-cell engagers
Ongoing and
Completed Studies


  • For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

Product Monograph / Prescribing Information

Document TitleYearSource
Talvey (talquetamab-tgvs) Prescribing Information.2023Janssen Biotech, Inc., Horsham, PA

Randomized Controlled Trials